Last reviewed · How we verify

SPC4001

Shin Poong Pharmaceutical Co. Ltd. · Phase 2 active Small molecule ✓ Verified Jun 2026

SPC4001 is a Small molecule drug developed by Shin Poong Pharmaceutical Co. Ltd.. It is currently in Phase 2 development. Also known as: Amlodipine 5mg.

SPC4001 is not mentioned in the provided facts, but SPC1001 is being studied for the treatment of Essential Hypertension. The study involves comparing the efficacy and safety of SPC1001 with monotherapy in patients with Essential Hypertension.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameSPC4001
Also known asAmlodipine 5mg
SponsorShin Poong Pharmaceutical Co. Ltd.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SPC4001

What is SPC4001?

SPC4001 is a Small molecule drug developed by Shin Poong Pharmaceutical Co. Ltd..

Who makes SPC4001?

SPC4001 is developed by Shin Poong Pharmaceutical Co. Ltd. (see full Shin Poong Pharmaceutical Co. Ltd. pipeline at /company/shin-poong-pharmaceutical-co-ltd).

Is SPC4001 also known as anything else?

SPC4001 is also known as Amlodipine 5mg.

What development phase is SPC4001 in?

SPC4001 is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing